Analysts Release Ratings on These Healthcare Stocks in Mid-December

Stock analysts initiated coverage in the Healthcare sector for the week ending December 16th, 2011 for the following companies:

Complete Genomics (NASDAQ:GNOM): MLV & Co initiated coverage of this company with a rating of Buy and a price target of $7 on Dec 14th. The shares recently traded at $2.76, down $0.05, or 1.78% since the analyst’s rating. About the company: Complete Genomics Inc. is a biomedical company. The Company discovers genome sequencing of human populations using DNA that allows large-scale human genome studies. Get the most recent company news and stock data here >>

CareFusion (NYSE:CFN): Morgan Keegan initiated coverage of this company with a rating of Mkt Perform and a price target of $28 on Dec 14th. The shares recently traded at $23.95, down $0.06, or 0.25% since the analyst’s rating. About the company: CareFusion Corporation provides health care products and services. The Company offers products that focus on breaking the cycle of harmful medication errors and reducing hospital acquired infections. CareFusion’s products include IV pumps, automated dispensing and patient identification systems, electronic infection surveillance service, and ventilation and respiratory products. Get the most recent company news and stock data here >>

Solta Medical (NASDAQ:SLTM): Morgan Keegan initiated coverage of this company with a rating of Mkt Perform and a price target of $3.5 on Dec 14th. The shares recently traded at $2.87, down $0.1, or 3.37% since the analyst’s rating. About the company: Solta Medical, Inc. designs, develops, manufactures and markets medical devices for the non-invasive treatment of wrinkles. Get the most recent company news and stock data here >>

Alnylam Pharma (NASDAQ:ALNY): JMP Securities initiated coverage of this company with a rating of Mkt Outperform and a price target of $12 on Dec 15th. The shares recently traded at $7.62, down $0.28, or 3.54% since the analyst’s rating. About the company: Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company. The Company is developing technology that can specifically and potently silence disease-causing genes. Get the most recent company news and stock data here >>

Ziopharm Oncology (NASDAQ:ZIOP): Global Hunter Securities initiated coverage of this company with a rating of Buy and a price target of $9 on Dec 15th. The shares recently traded at $4.40, up $0.05, or 1.15% since the analyst’s rating. About the company: ZIOPHARM Oncology, Inc. is a biopharmaceutical company seeking to acquire, develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer drugs. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>